2021
Efficacy and safety of transcranial direct current stimulation as an add-on treatment for obsessive-compulsive disorder: a randomized, sham-controlled trial
Silva R, Brunoni A, Goerigk S, Batistuzzo M, Costa D, Diniz J, Padberg F, D’Urso G, Miguel E, Shavitt R. Efficacy and safety of transcranial direct current stimulation as an add-on treatment for obsessive-compulsive disorder: a randomized, sham-controlled trial. Neuropsychopharmacology 2021, 46: 1028-1034. PMID: 33452434, PMCID: PMC8115679, DOI: 10.1038/s41386-020-00928-w.Peer-Reviewed Original ResearchConceptsTreatment-resistant obsessive-compulsive disorderTranscranial direct current stimulationSupplementary motor areaBaseline Y-BOCS scoresActive transcranial direct current stimulationObsessive-compulsive disorderY-BOCS scoresDirect current stimulationAdverse eventsWeek 12Efficacy of tDCSCurrent stimulationCathodal transcranial direct current stimulationSham-controlled trialMild adverse eventsClinical Global ImpressionSham-controlled studyBetween-group differencesSymptoms of depressionSecondary outcomesPrimary outcomeImprovement subscaleGlobal ImpressionNeuromodulation therapiesTreatment resistance
2019
Kundalini Yoga Meditation Versus the Relaxation Response Meditation for Treating Adults With Obsessive-Compulsive Disorder: A Randomized Clinical Trial
Shannahoff-Khalsa D, Fernandes RY, de B. Pereira C, March JS, Leckman JF, Golshan S, Vieira MSR, Polanczyk GV, Miguel EC, Shavitt RG. Kundalini Yoga Meditation Versus the Relaxation Response Meditation for Treating Adults With Obsessive-Compulsive Disorder: A Randomized Clinical Trial. Frontiers In Psychiatry 2019, 10: 793. PMID: 31780963, PMCID: PMC6859828, DOI: 10.3389/fpsyt.2019.00793.Peer-Reviewed Original ResearchY-BOCS scoresFirst-line therapyObsessive-compulsive disorderClinical trialsSecondary measuresY-BOCSShort Form-36 Health SurveyBaseline Y-BOCS scoresCompulsive ScaleGreater improvementRelative efficacyClinical Global ImpressionEffective treatment scheduleYale-Brown Obsessive Compulsive ScaleHigh psychosocial impairmentBeck Depression InventoryBeck Anxiety InventoryLife-long disorderObsessive Compulsive ScaleYale-Brown ObsessiveYoga meditationLine therapyPrimary outcomeTreat analysisReuptake inhibitors
2017
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16
2014
Hoarding symptoms and prediction of poor response to limbic system surgery for treatment-refractory obsessive-compulsive disorder.
Gentil AF, Lopes AC, Dougherty DD, Rück C, Mataix-Cols D, Lukacs TL, Canteras MM, Eskandar EN, Larsson KJ, Hoexter MQ, Batistuzzo MC, Greenberg BD, Miguel EC. Hoarding symptoms and prediction of poor response to limbic system surgery for treatment-refractory obsessive-compulsive disorder. Journal Of Neurosurgery 2014, 121: 123-30. PMID: 24702323, DOI: 10.3171/2014.2.jns131423.Peer-Reviewed Original ResearchConceptsLimbic system surgeryClinical outcomesWorse responseMean Y-BOCS scoreTreatment-refractory obsessive-compulsive disorderSymptom dimensionsPreoperative symptom severityWorse clinical outcomesTreatment-refractory patientsYale-Brown Obsessive Compulsive ScaleY-BOCS scoresSymptom Checklist scoresHoarding dimensionObsessive Compulsive ScaleSurgery needObsessive-compulsive disorderSurgical modalitiesAblative surgeryPoor responseWorse outcomesTreatment outcomesDimensional Yale-Brown Obsessive Compulsive ScaleYBOCS scoresPatientsSurgery
2013
Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making
da Conceição Costa D, Shavitt R, Cesar R, Joaquim M, Borcato S, Valério C, Miguel E, Diniz J. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. Journal Of Psychiatric Research 2013, 47: 1700-1707. PMID: 23948637, DOI: 10.1016/j.jpsychires.2013.07.006.Peer-Reviewed Original ResearchConceptsBaseline Y-BOCS scoresSerotonin reuptake inhibitorsEarly improvementTreatment responseY-BOCS scoresBaseline Yale-Brown ObsessiveLogistic regressionAdequate pharmacological treatmentPotential predictive factorsWeeks of treatmentGreater reductionObsessive-compulsive disorder patientsStepwise logistic regressionWarrants further investigationYale-Brown ObsessiveClinical featuresReuptake inhibitorsObsessive-compulsive disorderPharmacological treatmentPredictive factorsMajor depressionDisorder patientsOCD treatment responseCompulsive ScaleWeeks
2011
A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder
Diniz J, Shavitt R, Fossaluza V, Koran L, de Bragança Pereira C, Miguel E. A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder. Journal Of Clinical Psychopharmacology 2011, 31: 763-768. PMID: 22020357, DOI: 10.1097/jcp.0b013e3182367aee.Peer-Reviewed Original ResearchConceptsY-BOCS scoresFluoxetine groupTreatment regimenSelective serotonin reuptake inhibitorsPlacebo-controlled trialSevere adverse eventsSerotonin reuptake inhibitorsMain outcome measuresObsessive-compulsive disorder patientsCompulsive Scale scoresYale-Brown ObsessiveFluoxetine monotherapyAdverse eventsReuptake inhibitorsObsessive-compulsive disorderPrimary diagnosisOutcome measuresDisorder patientsScale scoreFluoxetineMental disordersQuetiapinePatientsStatistical ManualClomipramineGroup cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: A practical clinical trial
Belotto-Silva C, Diniz J, Malavazzi D, Valério C, Fossaluza V, Borcato S, Seixas A, Morelli D, Miguel E, Shavitt R. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: A practical clinical trial. Journal Of Anxiety Disorders 2011, 26: 25-31. PMID: 21907540, DOI: 10.1016/j.janxdis.2011.08.008.Peer-Reviewed Original ResearchConceptsGroup cognitive behavioral therapyY-BOCS scoresPsychiatric comorbidityCognitive behavioral therapySSRI groupMean Y-BOCS scoreSelective serotonin reuptake inhibitorsBaseline Y-BOCS scoresY-BOCS reductionSerotonin reuptake inhibitorsMore psychiatric comorbiditiesPractical clinical trialsReal-world populationObsessive-compulsive disorder outpatientsBroad inclusion criteriaAdditional psychiatric comorbidityReuptake inhibitorsObsessive-compulsive disorderClinical effectivenessClinical trialsMajor depressionCGI ratingsInclusion criteriaComorbiditiesWorse response